Vaccine effectiveness in older individuals: What has been learned from the influenza-vaccine experience

Ageing Research Reviews

Volumn 10, Issue 3, 2011, Pages 389-395

  Lang, Pierre Olivier ^a,b   Govind, Sheila ^a   Mitchell, Wayne A ^a   Siegrist, Claire Anne ^b   Aspinall, Richard ^a  

^a CRANFIELD UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Cell mediated immunity; Hemagglutinin inhibition; Immunosenescence; Influenza vaccine effectiveness; Innate immunity; Older adults

Indexed keywords

ANTIBODY; HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE;

ADAPTIVE IMMUNITY; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; REVIEW; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; AGED; AGED, 80 AND OVER; AGING; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; TREATMENT OUTCOME;

EID: 79955949208     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2010.09.005     Document Type: Review

References (110)

1. Aspinall R., Goronzy J.J. Immune senescence. Curr. Opin. Immunol. 2010, 22:497-499.
2. Aspinall R., Pido J., Andrew D. A simple method for the measurement of sjTREC levels in blood. Mech. Ageing Dev. 2000, 121:59-67.
3. Aspinall R., Pitts D., Lapenna A., Mitchell W. Immunity in the elderly: the role of the thymus. J. Comp. Pathol. 2010, 142(Suppl. 1):S111-S115.
4. Beyer W.E.P., Palache A.M., Baljet M., Masurel N. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 1989, 7:385-394.
5. Bianchi E., Liang X., Ingallinella P., Finotto M., Chastain M.A., Fan J., Fu T.M., Song H.C., Horton M.S., Freed D.C., Manger W., Wen E., Shi L., Ionescu R., Price C., Wenger M., Emini E.A., Cortese R., Ciliberto G., Shiver J.W., Pessi A. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J. Virol. 2005, 79:7380-7388.
6. Brydak L.B., Machala M., Mysliwska J., Mysliwski A., Trzonkowski P. Immune response to influenza vaccination in an elderly population. J. Clin. Immunol. 2003, 23:214-222.
7. Buxton J.A., Skowronski D.M., Ng H., et al. Influenza revaccination of elderly travellers: antibody response to single influenza vaccination and revaccination at 12 weeks. J. Infect. Dis. 2001, 184:188-191.
8. Cate T.R., Rayford Y., Niño D., Winokur P., Brady R., Belshe R., Chen W., Atmar R.L., Couch R.B. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2009, (Epub ahead of print).
9. Centers for Disease Control and Prevention Recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep. 2004, 53(RR-06):1-40.
10. Chan L., Doctor J.N., MacLehose R.F., Lawson H., Rosenblatt R.A., Baldwin LM Jha A Do Medicare patients with disabilities receive preventive services? A population based study. Arch. Phys. Med. Rehabil. 1999, 80:642-646.
11. Cox M.M., Hollister J.R. FluBlok a next generation influenza vaccine manufactured in insect cells. Biologicals 2009, 37:182-189.
12. de Bruijn I.A., Nauta J., Gerez L., Palache A.M. The virosomal influenza vaccine Invivac: immunogeneicity and tolerability compared to adjuvanted influenza vaccine (Fluad) in elderly subjects. Vaccine 2006, 24:6629-6631.
13. De Villiers P.J., Steele A.D., Hiemstra L.A., Rappaport R., Dunning A.J., Gruber W.C., Forrest B.D. LAIV Elderly Study Trial Network. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 2009, 28:228-234.
14. Deans G.D., Stiver H.G., McElhaney J.E. Influenza vaccines provide diminished protection but are cost-saving in older adults. J. Intern. Med. 2010, 267:220-227.
15. Delafuente J.C., Davis J.A., Meuleman J.R., Jones R.A. Influenza vaccination and warfarin anticoagulation: a comparison of subcutaneous and intramuscular routes of administration in elderly men. Pharmacotherapy 1998, 18:631-636.
16. Drape R.J., Macklin M.D., Barr L.J., Jones S., Haynes J.R., Dean H.J. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006, 24:4475-4481.
17. Effros R.B. Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine 2007, 25:259-604.
18. Effros R.B. Telomerase induction in T cells: a cure for aging and disease?. Exp. Gerontol. 2007, 42:416-420.
19. Falsey A.R., Treanor J.J., Tornieporth N., Capellan J., Gorse G.J. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J. Infect. Dis. 2009, 200:172-180.
20. Fauce S.R., Jamesion B.D., Chin A.C., Mitsuyasu R.T., Parish S.T., Ng H.L., Kitchen C.M., Yang O.O., Harley C.B., Effros R.B. Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J. Immunol. 2008, 181:7400-7406.
21. Feng J.Q., Gulati U., Zhang X., Keitel W.A., Thompson D.M., James J.A., Thompson L.F., Air G.M. Antibody quantity versus quality after influenza vaccination. Vaccine 2009, 27:6358-6362.
22. Fiore A.E., Shay D.K., Broder K., Iskander J.K., Uyeki T.M., Mootrey G., Bresee J.S., Cox N.S., Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practice (ACIP) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Morb. Mortal. Wkly. Rep. 2008, 57(RR-7):1-60.
23. Fireman B., Lee J., Lewis N., Bembom O., van der Laan M., Baxter M. Influenza vaccination and mortality: differentiating vaccine effects from bias. Am. J. Epidemiol. 2009, 170:650-656.
24. Fulop T., Pawelec G., Castle S., Loeb M. Immunosenescence and vaccination in nursing home. Clin. Infect. Dis. 2009, 48:443-448.
25. Gavazzi G., Krause K.H. Ageing and infection. Lancet Infect. Dis. 2002, 2:659-666.
26. Glenn G.M., Thomas D.N., Poffenberger K.L., Flyer D.C., Ellingsworth L.R., Andersen B.H., Frech S.A. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when co-administered with a heat-labile enterotoxin (LT) adjuvant patch. Vaccine 2009, 27(Suppl. 6):G60-G66.
27. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccine in the elderly: a quantitative review. Vaccine 2006, 24:6808-6811.
28. Goveart T.M., Thijs C.T., Masurel N., Sprenger M.J., Dinant G.J., Knottnerus J.A. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994, 272:1661-1665.
29. Greenberg H.B., Piedra P.A. Immunization against viral respiratory disease: a review. Pediatr. Infect. Dis. J. 2004, 23(Suppl. 11):S254-S261.
30. Grubeck-Loebenstein B., Della Bella S., Iorio A.M., Michel J.P., Pawelec G., Solana R. Immunosenescence and vaccine failure in the elderly. Aging Clin. Exp. Res. 2009, 21:201-209.
31. Haines C.J., Giffon T.D., Lu L.S., Lu X., Tessier-Lavigne M., Ross D.T., Lewis D.B. Human CD4+ T cells recent thymic emigrants are identified by protein tyrosine kinase 7 and have reduced immune function. J. Exp. Med. 2009, 206:275-285.
32. Hak E., Verheij T.J., Grobbee D.E., Nichol K.L., Hoes A.W. Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. J. Epidemiol. Community Health 2002, 56:951-955.
33. Hak E., Hoes A.W., Nordin J., Nichol K.L. Benefits of influenza vaccine in US elderly-appreciating issues of confounding, bias and precision. Int. J. Epidemiol. 2006, 35:800-802.
34. Hirokawa K., Utsuyama M., Ishikawa T., Kikuchi Y., Kitagawa M., Fujii Y., Nariuchi H., Uetake H., Sugihara K. Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells. Mech. Ageing Dev. 2009, 130:86-91.
35. Holland D., Booy R., De Looze F., Eizenberg P., McDonald J., Karrasch J., McKeirnan M., Salem H., Mills G., Reid J., Weber F., Saville M. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 2008, 198:650-658.
36. Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache A.M., Wilschut J. The virosome concept for influenza vaccines. Vaccine 2005, 23(Suppl. 1):S26-38.
37. Hui S.L., Chu L.W., Peiris J.S., Chan K.H., Chu D., Tsui W. Immune response to influenza vaccination in community-dwelling Chinese elderly persons. Vaccine 2006, 24:5371-5380.
38. Hünig T., Lüdher F., Elflein K., Gogishvili T., Fröhlich M., Guler R., Culter A., Brombacher F. CD28 and IL-4: two heavyweights controlling the balance between immunity and inflammation. Med. Microbiol. Immunol. 2010, (Epub ahead of print).
39. Iezzoni L.I., McCarthy E.P., Davis R.B., Siebens H. Mobility impairments and use of screening and preventive services. Am. J. Public Health 2000, 90:955-961.
40. Influenza, 2008. (accessed 30.04.10). http://www.who.int/mediacentre/factsheets/fs211/en/.
41. Jackson L.A. Benefits of examining influenza vaccine associations outside of influenza season. Am. J. Respir. Crit. Care Med. 2008, 178:439-440.
42. Jackson L.A., Jackson M.L., Nelson J.C., Neuzil K.M., Weiss N.S. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int. J. Epidemiol. 2006, 35:337-344.
43. Jackson L.A., Nelson J.C., Benson P., Neuzil K.M., Reid R.J., Psaty B.M., Heckbert S.R., Larson E.B., Weiss N.S. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int. J. Epidemiol. 2006, 35:345-352.
44. Jackson M.L., Nelson J.C., Weiss N.S., Neuzil K.M., Barlow W., Jackson L.A. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 2008, 372:398-405.
45. Jefferson T. Influenza vaccination: policy versus evidence. BMJ 2006, 333:912-915.
46. Jefferson T., Rivetti D., Rivetti A., Rudin M., Di Pietrantonj C., Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005, 366:1165-1174.
47. Jefferson T.O., Rivetti D., Di Pietrantonj C., Rivetti A., Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. 2007, CD001269.
48. Jefferson T., Di Pietrantonj C., Al-Ansary L.A., Ferroni E., Thorning S., Thomas R.E. Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev. 2010, 17:CD004876.
49. Keitel W.A., Campbell J.D., Treanor J.J., Walter E.B., Patel S.M., He F., Noah D.L., Hill H. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminium hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J. Infect. Dis. 2008, 198:1309-1316.
50. Keylock K.T., Lowder T., Leifheit K.A., et al. Higher antibody, but not cell-mediated, responses to vaccination in high physically fit elderly. J. Appl. Physiol. 2007, 102:1090-1098.
51. Kohler S., Wagner U., Pierer M., Kimming S., Oppmann B., Mowes B., Julke K., Romagnani C., Thiel A. Post-thymic in vivo proliferation of naive CD4+ T cells constrains the TCR repertoire in healthy human adults. Eur. J. Immunol. 2005, 35:1987-1994.
52. Lang A., Brien J.D., Messaoudi I., Nikolich-Zugich J. Age-related dysregulation of CD8+ T cell memory specific for a persistent virus is independent of viral replication. J. Immunol. 2008, 180:4848-4857.
53. Lang A., Brien J.D., Nikolich-Zugich J. Inflation and long-term maintenance of CD8 T cells responding to a latent herpes virus depend upon establishment of latency and presence of viral antigens. J. Immunol. 2009, 183:8077-8087.
54. Leroux-Roels I., Vets E., Freese R., Seiberling M., Weber F., Salamand C., Leroux-Roels G. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine 2008, 26:6614-6619.
55. Leroux-Roels I.RF., Forgus S., Maes C., De Boever F., Dramé M., Gillard P., van der Most R., Van Mechelen M., Hanon E., Leroux-Roels G. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterogeneous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010, 28:849-857.
56. Livingston B.D., Higgins D., Van Nest G. Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. BioDrugs 2006, 20:335-340.
57. Maciosek M.V., Solberg L.I., Coffield A.B., Edwards N.M., Goodman M.J. Influenza vaccination health impact and cost effectiveness among adults aged 50-64 and 65 and older. Am. J. Prev. Med. 2006, 31:72-79.
58. MacKenzie J.S. Influenza subunit vaccine: antibody responses to one and two doses of vaccine and length of response, with particular reference to the elderly. Br. Med. J. 1977, 1:200-202.
59. McElhaney J.E. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005, 23(Suppl. 1):S10-S25.
60. McElhaney J.E., Meneilly G.S., Lechelt K.E., Beattie B.L., Bleackley R.C. Antibody response to whole-virus and split-virus influenza vaccines in successful ageing. Vaccine 1993, 11:1055-1060.
61. McGuire L.C., Strine T.W., Okoro C.A., Ahluwalia I.B., Ford E.S. Healthy lifestyle behaviours among older US adults with and without disabilities. Behavioral risk factor surveillance system, 2003. Prev. Chronic Dis. [Online Serial] 2007, 4:1-11. Available at: http://www.cdc.gov/pcd/issues/2007/jan/06 0029.htm.
62. Michel, J.P., Lang, P.O., 2011. Promoting life course vaccination. Rejuvenation Res., in press.
63. Miller E., Hoschler K., Hardelid P., Stanford E., Andrews N., Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010, 375:1100-1108.
64. Minutello M., Senatore F., Cecchinelli G., et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999, 17:99-104.
65. Mitchell W.A., Aspinall R. Interleukine-7 and immunorejuvenation. Handbook of Immunosenescence: Basic Understanding and Clinical Applications 2009, 1516-1546. Springer Science+Business Media BV. T. Fulop, C. Franceschi, K. Hirokawa, G. Pawelec (Eds.).
66. Mitchell W.A., Lang P.O., Aspinall R. Tracing thymic output in older individuals. Clin. Exp. Immunol. 2010, 161:497-503.
67. Molinari N.A., Ortega-Sanchez I.R., Messonier M.L., Thompson W.W., Wortley P.M., Weintraub E., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25:5086-5096.
68. Monto A.S., Hornbuckle K., Ohmit S.E. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am. J. Epidemiol. 2001, 154:155-160.
69. Monto A.S., Ansaldi F., Aspinall R., McElhaney J.E., Montaño L.F., Nichol K.L., Puig-Barberà J., Schmitt J., Stephenson I. Influenza control in the 21st century: optimizing protection for older adults. Vaccine 2009, 27:5043-5053.
70. Mullooly J.P., Bennett M.D., Hornbrook M.C., Barker W.H., Williams W.W., Patriarca P.A., Rhodes P.H. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann. Intern. Med. 1994, 121:947-952.
71. Mysliwska J., Trzonkowski P., Szmit E., Brydak L.B., Machala M., Mysliwski A. Immunomodulating effect of influenza vaccination in the elderly differing in health status. Exp. Gerontol. 2004, 39:1447-1458.
72. Nelson J.C., Jackson M.L., Weiss N.S., Jackson L.A. New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among senior. J. Clin. Epidemiol. 2009, 62:687-694.
73. Nichol K.L. Challenges in evaluating influenza vaccine effectiveness and the mortality benefits controversy. Vaccine 2009, 27:6305-6311.
74. Nichol K.L., Wuorenma J., von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch. Intern. Med. 1998, 158:1769-1776.
75. Nichol K.L., Nordin J.D., Nelson D.B., Mullooly J.P., Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N. Engl. J. Med. 2007, 357:1373-1381.
76. Note for Guidance on Harmonization of Requirements for Influenza Vaccines, 1997, March 12. CPMP/BWP/214/96 (circular 96-0666): 1-22.) (accessed 30.04.10). http://www.emea.europa.eu/pdfs/human/bwp/021496en.pdf.
77. Panda A., Qian F., Mohanty S., van Duin D., Newman F.K., Zhang L., Chen S., Towle V., Belshe R.B., Fikrig E., Allore H.G., Montgomery R.R., Shaw A.C. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J. Immunol. 2010, 184:2518-2527.
78. Patriarca P.A., Weber J.A., Parker R.A., Hall W.M., Kendal A.P., Bregman D.J., Schonberger L.B. Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 1985, 253:1136-1139.
79. Pawelec G., Derhovanessian E., Larbi A., Strindhall J., Wikby A. Cytomegalovirus and human immunosenescence. Rev. Med. Virol. 2009, 19:47-56.
80. Pegliasco F., Mensi C., Serpilli W., Speccher L., Masella P., Belloni A. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano) 2001, 13:38-43.
81. Peters N.L., Meiklejohn G., Jahnigen D.W. Antibody response of an elderly population to a supplemental dose of influenza B vaccine. J. Am. Geriatr. Soc. 1988, 36:593-599.
82. Poland G.A., Jacobson R.M., Ovsyannikova I.G. Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine movement, and vaccinomics. Vaccine 2009, 27:3240-3244.
83. Powers D.C., Hanscome P.J., Pietrobon P.J.F. In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant. Vaccine 1995, 13:1330-1335.
84. Praditsuwan R., Assantachai P., Wasi C., Puthavatana P., Kositanont U. The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community. J. Med. Assoc. Thai. 2005, 88:256-264.
85. Rivetti D., Jefferson T., Thomas R., Rudin M., Rivetti A., Di Pietrantonj C., Demicheli V. Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev. 2006, 3:CD004876.
86. Roman F., Vaman T., Gerlach B., Markendorf A., Gillard P., Devaster J.M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised-trial. Vaccine 2010, 28:1740-1745.
87. Rosenberg S.A., Sportes C., Ahmadzadeh M., Fry T.J., Ngo L.T., Schwarz S.L., Stetler-Stevenson M., Morton K.E., Mavroukakis S.A., Morre M., Buffet R., Mackall C.L., Gress R.E. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother. 2006, 29:313-319.
88. Ruf B.R., Colberg K., Frick M., Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 2004, 32:191-198.
89. Sambhara S., McElhaney J.E. Immunosenescence and influenza vaccine efficacy. Curr. Top. Microbiol. Immunol. 2009, 333:413-429.
90. Sasaki S., He X.S., Holmes T.H., Dekker C.L., Kemble G.W., Arvin A.M. Greenberg HB Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 2008, 3:e2975.
91. Seasonal Human Influenza and Vaccination, 2010.) (accessed 30.04.10). http://www.ecdc.europa.eu/en/press/Press%2520Releases/071012_PR_SI_Prof_Fact_Sheet.pdf.
92. Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 2009, 9:185-193.
93. Simonsen L., Taylor R.J., Viboud C., Miller M.A., Jackson L.A. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect. Dis. 2007, 7:658-666.
94. Simonsen L., Viboud C., Taylor R.J., Miller M.A., Jackson L.A. Influenza vaccination and mortality benefits: new insights, new opportunity. Vaccine 2009, 27:6300-6304.
95. Skowronski D.M., Tweed S.A., De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?. J. Infect. Dis. 2008, 197:490-502.
96. Smith N.M., Bresee J.S., Shay D.K., Uyeki T.M., Cox N.J., Strikas R.A. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep. 2006, 55(RR-10):1-42.
97. Strindhall J., Nilsson B.O., lofgren S., Ernerudh, Pawelec G., Johansson B., Wikby A. No immune risk profile among individuals who reach 100 years of age findings from the Swedish NONA immune longitudinal study. Exp. Gerontol. 2007, 42:753-761.
98. Thompson W.W., Moore M.R., Weintraub E., Cheng P.Y., Jin X., Bridges C.B., Bresee J.S., Shay D.K. Estimating influenza-associated deaths in the United States. Am. J. Public Health 2009, 99(Suppl. 2):S225-S230.
99. Treanor J.J., Schiff G.M., Hayden F.G., Brady R.C., Hay C.M., Meyer A.L., Holden-Wiltse J., Liang H., Gilbert A., Cox M. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007, 297:1577-1582.
100. Trzonkowski P., Mysliwska J., Szmit E., et al. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination-an impact of immunosenescence. Vaccine 2003, 21:3826-3836.
101. Vallejo A.N. CD28 extinction in human T-cells: altered functions and the program of T-cell senescence. Immunol. Rev. 2005, 205:158-169.
102. Van Hoecke C., Prikazsky V., Uto I., Menschikowski C. Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients. Gerontology 1996, 42:190-198.
103. Virgin H.W., Wherry E.J., Ahmed R. Redefining chronic viral infection. Cell 2009, 138:30-50.
104. Voordouw B.C., van der Linden P.D., Simonian S., van der Lei J., Sturkenboom M.C., Stricker B.H. Influenza vaccination in community-dwelling elderly: impact on mortality and influenza-associated morbidity. Arch. Intern. Med. 2003, 163:1089-1094.
105. Vu T., Farish S., Jenkins M., Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002, 20:1831-1836.
106. Weiskopf D., Weinberger D., Grubeck-Loebenstein B. The aging of the immune system. Transpl. Int. 2009, 22:1041-1050.
107. Wikby A., Månsson I.A., Johansson B., Strindhall J., Nilsson S.E. The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20-100 years of age. Biogerontology 2008, 9:299-308.
108. World Health Organization Influenza vaccines. Wkly. Epidemiol. Rec. 2005, 80:279-287.
109. Xakellis G.C. Predictors of influenza immunization in persons over age 65. J. Am. Board Fam. Pract. 2005, 18:426-433.
110. Yu X., Tsibane T., McGraw P.A., House F.S., Keefer C.J., Hicar M.D., Tumpey T.M., Pappas C., Perrone L.A., Martinez O., Stevens J., Wilson I.A., Aguilar P.V., Altschuler E.L., Basler C.F., Crowe J.E. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008, 455:532-536.